#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma stage IV Trigeminal neuralgia Central nervous system neoplasm Idiopathic inflammatory myopathy Postprandial hypoglycaemia Systemic mastocytosis Endometrial cancer recurrent Oesophageal achalasia Muscular dystrophy Vascular calcification Crohn's disease Hairy cell leukaemia Acute respiratory distress syndrome Mantle cell lymphoma recurrent Chronic myeloid leukaemia More trials…

    Learn about Rare Diseases

    Osteosarcoma metastatic Netherton’s syndrome Mitochondrial myopathy – Basic Information Atypical haemolytic uraemic syndrome – Trials in Disease Glycogen storage disease type II – Life with Disease Factor VIII deficiency Haemophilia – Diagnostics Primary mediastinal large B-cell lymphoma – Treatment Cholangitis sclerosing – Life with Disease Leiomyosarcoma recurrent More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vibozilimod Simvastatin Celecoxib Dosulepin Hydrochloride Lutetium (177Lu) Edotreotide [89ZR]ZR-DFO-CIT-013 Interferon Beta-1B Dutasteride Apraglutide Oxcarbazepine Tinengotinib Tolvaptan Zidovudine Lisocabtagene Maraleucel Bms-986449-03 Pbf-999 Prasterone Prednisone Milvexian Leuprorelin More therapies…

    Learn about Your Condition

    Colorectal cancer stage II Procedural headache Myofascial pain syndrome Peritoneal neoplasm Lichen planus Peripheral artery restenosis Non-small cell lung cancer Pulmonary tuberculosis Subarachnoid haemorrhage Herpes simplex reactivation Neonatal hyperglycaemia Leiomyosarcoma Mesothelioma malignant Metastatic glioma Chondrosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Parkinson’s disease

  • Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson’s Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
    Austria France Germany Italy The Netherlands Poland +1

  • Study on the Safety and Effects of Afamelanotide for Patients with Early Parkinson’s Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Afamelanotide
    Spain

  • Study on the Long-Term Safety of Tavapadon for Patients with Parkinson’s Disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Tavapadon
    Bulgaria Czechia France Germany Hungary Italy +2

  • Study on the Long-Term Safety of ND0612 (Carbidopa, Levodopa) Infusion for Patients with Advanced Parkinson’s Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Carbidopa
    • Levodopa
    Austria France Italy Poland

  • Study on the Long-Term Safety and Effectiveness of Minzasolmin and Iodine Ioflupane (123I) in Patients with Parkinson’s Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Ioflupane (123I)
    • Minzasolmin
    France Germany Italy The Netherlands Poland Spain

  • Study on BIA 28-6156 for Parkinson’s Disease in Patients with GBA1 Gene Variant

    Not recruiting

    2 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • 5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
    France Germany Italy The Netherlands Poland Portugal +2
Previous Page
1 … 6 7 8 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!